NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $111.76 -3.86 (-3.34%) (As of 12:30 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About BioNTech Stock (NASDAQ:BNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$111.52▼$117.1850-Day Range$78.36▼$124.7152-Week Range$76.53▼$131.49Volume818,791 shsAverage Volume781,286 shsMarket Capitalization$26.57 billionP/E Ratio223.52Dividend YieldN/APrice Target$120.31Consensus RatingModerate Buy Company OverviewBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More… This Crypto Is Set to Explode in September (Ad)With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now. BioNTech Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 44th PercentileBioNTech scored higher than 44% of companies evaluated by MarketBeat, and ranked 697th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageBioNTech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($2.80) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 225.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.52.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 225.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 147.59.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.09% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 16.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BioNTech is 306.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BioNTech's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.09% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 16.50%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.51 News SentimentBioNTech has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for BioNTech this week, compared to 10 articles on an average week.Search Interest42 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. BNTX Stock News HeadlinesModerna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (BNTX)Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.August 19, 2024 | marketbeat.comBioNTech Is More Than a Covid-19 Stock. It's Having a Great September.September 19 at 12:02 PM | barrons.comThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. September 19, 2024 | Crypto 101 Media (Ad)BioNTech (NASDAQ:BNTX) Hits New 1-Year High After Analyst UpgradeSeptember 19 at 2:41 AM | americanbankingnews.comJefferies Financial Group Upgrades BioNTech (NASDAQ:BNTX) to "Buy"September 19 at 2:03 AM | americanbankingnews.comJefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)September 18 at 11:05 PM | msn.comShort Interest in BioNTech SE (NASDAQ:BNTX) Decreases By 16.5%September 18 at 3:13 PM | americanbankingnews.comBioNTech (NASDAQ:BNTX) PT Raised to $150.00September 18 at 4:17 AM | americanbankingnews.comSee More Headlines BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $105.54 at the beginning of the year. Since then, BNTX stock has increased by 6.8% and is now trading at $112.75. View the best growth stocks for 2024 here. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Monday, August, 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $1.34. BioNTech's quarterly revenue was down 23.3% on a year-over-year basis. Does BioNTech have any subsidiaries? BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more. When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? Top institutional shareholders of BioNTech include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). Company Calendar Last Earnings8/05/2024Today9/19/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$120.31 High Stock Price Target$171.00 Low Stock Price Target$85.00 Potential Upside/Downside+5.2%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio228.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins-18.69% Pretax Margin-8.75% Return on Equity-2.54% Return on Assets-2.24% Debt Debt-to-Equity Ratio0.01 Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$2.69 billion Price / Sales10.10 Cash Flow$5.84 per share Price / Cash Flow19.58 Book Value$92.17 per share Price / Book1.24Miscellaneous Outstanding Shares237,726,000Free Float192,083,000Market Cap$27.18 billion OptionableOptionable Beta0.23 Social Links Should I Buy BioNTech Stock? BNTX Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BioNTech Bull Case Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE has shown resilience in the market despite recent challenges, indicating strong potential for growth. The company's innovative approach to developing immunotherapies for cancer and infectious diseases positions it well in the biotechnology sector. Recent institutional investments in BioNTech SE, such as Primecap Management Co. CA boosting its stake, reflect confidence from major players in the market. With a market capitalization of $20.25 billion, BioNTech SE is a significant player in the industry, offering stability and growth opportunities. The company's focus on cutting-edge research and development could lead to breakthrough treatments, driving stock price appreciation. BioNTech Bear Case Investors should be bearish about investing in BioNTech SE for these reasons: The company's recent earnings report showed a significant miss on EPS, which may raise concerns about its financial performance. BioNTech SE's revenue decline of 23.3% compared to the previous year indicates potential challenges in maintaining growth. Despite institutional investments, the stock's price-to-earnings ratio of 170.38 may be considered high, posing a risk for investors. The company's net margin of 4.01% suggests relatively low profitability compared to industry peers, impacting potential returns for investors. Analysts forecasting negative EPS for the current fiscal year could lead to short-term volatility in the stock price, affecting investor confidence. This page (NASDAQ:BNTX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding BioNTech SE You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.